Incidence and Burden of Pertussis Among Infants Less Than 1 Year of Age

Cristina Masseria, Carolyn K Martin, Girishanthy Krishnarajah, Laura K Becker, Ami Buikema, Tina Q Tan, Cristina Masseria, Carolyn K Martin, Girishanthy Krishnarajah, Laura K Becker, Ami Buikema, Tina Q Tan

Abstract

Background: Infant-specific pertussis data, especially among neonates, are limited and variable. This study (NCT01890850) provides overall and age-specific pertussis incidence and associated health care utilization and costs among commercially insured infants in the US.

Methods: Nearly 1.2 million infants born from 2005 to 2010 with commercial health plan coverage were followed during their first 12 months of life. Pertussis cases were identified from medical claims (International Classification of Diseases, 9th revision, Clinical Modification code: 033.0, 033.9, 484.3), and incidence rates were calculated. Each pertussis case was then matched to 10 comparators, so pertussis-related health care utilization and costs before and after the index date could be assessed.

Results: The overall pertussis incidence rate among infants <12 months of age was 117.7/100,000 person-years; infants 3 months of age had the highest incidence rate (247.7/100,000 person-years). Infants diagnosed with pertussis were significantly more likely to have prior diagnoses of upper respiratory infection, cough and wheezing-related illnesses than comparators (P < 0.001). Pertussis cases were more likely to be hospitalized within 14 days after the index date (31.8% vs. 0.5%; P < 0.001) and their adjusted health care costs during follow-up were 2.82 times higher than comparators (P < 0.001; 95% confidence interval: 2.08-3.81). The incremental cost of pertussis during the 12-month follow-up period averaged $8271 (P < 0.001). The average incremental cost varied substantially by age, ranging from $18,781 (P < 0.001) to $3772 (P = 0.02) among infants 1 month and 7-12 months of age, respectively.

Conclusions: The health burden of pertussis, particularly in the youngest infants, remains substantial, highlighting the need to intensify efforts to protect this most vulnerable population.

Conflict of interest statement

The conflict of interest and funding statements of the authors are listed in the Acknowledgements.

Figures

FIGURE 1.
FIGURE 1.
Incidence rates of pertussis by age in months from 2005 to 2010.
FIGURE 2.
FIGURE 2.
Percentage of infants with pertussis hospitalized on or within 14 days of index date.
FIGURE 3.
FIGURE 3.
Average length of inpatient hospitalization among infants with pertussis hospitalized on or within 14 days of index date.
FIGURE 4.
FIGURE 4.
Average follow-up cost difference by age group and utilization type.

References

    1. Munoz FM, Keitel WA. Progress in the diagnosis, prevention, and treatment of pertussis. Curr Infect Dis Rep. 2003;5:213–219.
    1. Wells KB, Omer SB. The financial impact of a state adopting a personal/philosophical belief exemption policy: modeling the cost of pertussis disease in infants, children and adolescents. Vaccine. 2012;30:5901–5904.
    1. Omer SB, Enger KS, Moulton LH, et al. Geographic clustering of nonmedical exemptions to school immunization requirements and associations with geographic clustering of pertussis. Am J Epidemiol. 2008;168:1389–1396.
    1. O’Brien JA, Caro JJ. Hospitalization for pertussis: profiles and case costs by age. BMC Infect Dis. 2005;5:57.
    1. Izurieta HS, Kenyon TA, Strebel PM, et al. Risk factors for pertussis in young infants during an outbreak in Chicago in 1993. Clin Infect Dis. 1996;22:503–507.
    1. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005;18:326–382.
    1. Centers for Disease Control and Prevention. Chapter 15, Pertussis. In: Atkinson W, Hamborsky J, Wolfe S, editors. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th ed. Washington DC: Public Health Foundation; 2012. pp. 215–232. 2nd printing.
    1. Centers for Disease Control and Prevention (CDC) Pertussis–United States, 1997–2000. MMWR Morb Mortal Wkly Rep. 2002;51:73–76.
    1. Jajosky RA, Hall PA, Adams DA, et al. Centers for Disease Control and Prevention (CDC) Summary of Notifiable diseases–United States, 2004. MMWR Morb Mortal Wkly Rep. 2006;53:1–79.
    1. Centers for Disease Control and Prevention (CDC) Pertussis–United States, 2001–2003. MMWR Morb Mortal Wkly Rep. 2005;54:1283–1286.
    1. Centers for Disease Control and Prevention (CDC) Pertussis epidemic–Washington, 2012. MMWR Morb Mortal Wkly Rep. 2012;61:517–522.
    1. Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367:1012–1019.
    1. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000;19:3219–3236.
    1. Cameron AC, Trivedi PK. Microeconomics Using Stata. College Station: Stata Press; 2009.
    1. United States Department of Labor. Bureau of Labor Statistics. Series ID: SUUR0000SAM. Washington, DC: United States. Department of Labor, Bureau of Labor Statistics; 2013. Consumer Price Index. Chained Consumer Price Index for All Urban Consumers (C-CPI-U) 1999–2013, Medical Care. Available at: .
    1. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ. 1999;18:153–171.
    1. Centers for Disease Control and Prevention (CDC) Summary of Notifiable Diseases–United States 2010. MMWR Morb Mortal Wkly Rep. 2012;59:1–111.
    1. Terranella A, Asay GR, Messonnier ML, et al. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis. Pediatrics. 2013;131:e1748–e1756.
    1. Haberling DL, Holman RC, Paddock CD, et al. Infant and maternal risk factors for pertussis-related infant mortality in the United States, 1999 to 2004. Pediatr Infect Dis J. 2009;28:194–198.
    1. Centers for Disease Control and Prevention (CDC) Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in Pregnant Women–Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013;62:131–135.
    1. Atkins KE, Fitzpatrick MC, Galvani AP, et al. Cost-effectiveness of pertussis vaccination during pregnancy in the United States. Am J Epidemiol. 2016;183:1159–1170.

Source: PubMed

3
Prenumerera